Not Yet RecruitingPhase 2

Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis

10 participantsStarted 2025-07-01

Plain-language summary

This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age: 18 to 60 years old;
✓. A clear diagnosis of aPAP must meet at least one of the following diagnostic criteria:

Exclusion criteria

✕. Secondary PAP (such as secondary to blood diseases, etc.);
✕. Patients with obvious pulmonary fibrosis, emphysema or irreversible lung function impairment;
✕. Patients in the acute exacerbation stage;
✕. Patients with other lung diseases (such as active pulmonary tuberculosis, bronchiectasis with purulent infection or other chronic infections; Have severe asthma, chronic bronchospasm, etc.
✕. Have a history of allergy to GM-CSF antibodies or related drug components;
✕. Patients who have participated in other clinical drug trials within the past three months;
✕. Patients who have experienced severe complications related to bronchoscopy or are intolerant to bronchoscopy;
✕. Concurrent with other serious cardiovascular and cerebrovascular diseases, hematological disorders, malignant tumors, etc.

What they're measuring

Chest HRCT

Timeframe: 12 weeks

Trial details

NCT IDNCT06989333

SponsorJiuwu Bai

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-30

Contact for this trial

Jiu-Wu Bai Doctor

13651602925 yv59@163.com

View on ClinicalTrials.gov More Pulmonary Alveolar Proteinosis trials